Literature DB >> 18475161

The metabolic syndrome: similar deleterious impact on all-cause mortality in hypertensive and normotensive subjects.

Bruno Pannier1, Frédérique Thomas, Kathy Bean, Bertrand Jégo, Athanase Benetos, Louis Guize.   

Abstract

OBJECTIVES: Few data are available on the impact of the metabolic syndrome on all-cause mortality risk according to the presence of hypertension. Our aim was to evaluate the 5-year impact of the metabolic syndrome, according to blood pressure status, on all-cause mortality risk in a large French population.
METHODS: The study population included 39 998 men and 20 756 women with no personal history of cardiovascular disease, who had a health check-up at the IPC Center (Paris, France) between 1999 and 2002, and who were followed up for 4.7 +/- 1.2 years. The metabolic syndrome was defined according to the National Cholesterol Educational Program classification (2001). Cox regression models were used to evaluate risk of all-cause mortality after adjustment for age, sex, classical risk factors and socioeconomic categories. Subjects were classified according to blood pressure status: hypertensive subject (systolic blood pressure > or =140 mmHg and/or diastolic blood pressure > or =90 mmHg or treatment) and normotensive subject.
RESULTS: The risk of all-cause mortality associated with the metabolic syndrome was 1.50 (1.24-1.82) [hazard ratio (HR) (95% confidence interval)]. The risk of all-cause mortality associated with the presence of hypertension was 1.60 (1.38-1.85). During the 4.7 years of follow-up, the impact of the metabolic syndrome was similar among normotensive and hypertensive subjects [HR: 1.09 (0.68-1.75) and 1.40 (1.13-1.74), respectively, P for interaction = 0.35].
CONCLUSION: The findings from this study show that, in a large middle-aged French population, the metabolic syndrome has the same deleterious impact on all-cause mortality in hypertensive subjects and normotensive subjects.

Entities:  

Mesh:

Year:  2008        PMID: 18475161     DOI: 10.1097/HJH.0b013e3282fd9936

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  Metabolic syndrome in hypertensive patients: An unholy alliance.

Authors:  Giuseppe Mulè; Ilenia Calcaterra; Emilio Nardi; Giovanni Cerasola; Santina Cottone
Journal:  World J Cardiol       Date:  2014-09-26

2.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly.

Authors:  Celeste M Vinluan; Hala H Zreikat; James R Levy; Kai I Cheang
Journal:  Metabolism       Date:  2011-08-15       Impact factor: 8.694

Review 4.  Update on the metabolic syndrome: hypertension.

Authors:  Kristi Reynolds; Rachel P Wildman
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

5.  Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies.

Authors:  Sang-Yhun Ju; June-Young Lee; Do-Hoon Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

6.  A Predictive Model of Metabolic Syndrome by Medical Examination: Evidence from an 8-Year Chinese Cohort.

Authors:  Huanyu Guo; Wenwei Jiang; Bo Zhao; Yanhua Xiong; Zhenya Lu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-08       Impact factor: 3.168

7.  Work economic sectors and cardiovascular risk factors: cross-sectional analysis based on the RECORD Study.

Authors:  Antoine Lewin; Frédérique Thomas; Bruno Pannier; Basile Chaix
Journal:  BMC Public Health       Date:  2014-07-24       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.